Healthcare
Live Price
Offline$0.0011
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 246 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ReNeuron Group plc (RNUGF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +31.5%, EPS growth of +44.3%, a dividend yield of 0.0%. What stands out right now is revenue +31.5%, EPS +44.3%, free cash flow +0.1% with operating margin -1342.5% and ROIC -105.5%. Valuation is more restrained than many high-expectation growth names at price/sales 0.1. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RNUGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RNUGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RNUGF Max Drawdown
-99.91%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RNUGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$49.0K
-99.2% YoY
FY Net Income
-$14.3M
-25.2% YoY
Free Cash Flow
-$12.2M
+15.6% YoY
Revenue Growth
+31.5%
EPS Growth
+44.3%
Gross Margin
-742.1%
Net Margin
-1020.4%
Income statement
GBP
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 530K | 403K | 257K | 6M | 49K |
| Gross Profit | -4M | -8M | -9M | -10M | -16M |
| Operating Income | -7M | -11M | -13M | -14M | -18M |
| EBITDA | -6M | -11M | -13M | -13M | -18M |
| Net Income | -5M | -10M | -11M | -11M | -14M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
GBP
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 10M | 15M | 13M | 20M |
| Total Assets | 10M | 17M | 25M | 20M | 31M |
| Total Liabilities | 5M | 7M | 6M | 7M | 7M |
| Shareholder Equity | 5M | 10M | 19M | 13M | 23M |
| Total Debt | 421K | 562K | 719K | 873K | 1M |
| Net Debt | -6M | -9M | -14M | -12M | -19M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+16.2% YoY
Capital Expenditures
188K
-58.0% YoY
Free Cash Flow
12M
+15.6% YoY
Key ratios
Gross Margin
-742.1%
Operating Margin
-1342.5%
Net Margin
-1020.4%
ROE
-72.4%
Debt / Equity
0.08x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.